An additive opinion to the committee opinion of ASRM and SART on the use of preimplantation genetic testing for aneuploidy (PGT-A)

Norbert Gleicher, David H. Barad, Pasquale Patrizio, Sonya Gayete-Lafuente, Andrea Weghofer, Zion Ben Rafael, Shizuko Takahashi, Demián Glujovsky, Ben W. Mol, Raoul Orvieto

Research output: Contribution to journalArticlepeer-review

Abstract

After over 20 years of progressively increasing clinical utilization of PGT-A (and its precursors), the American Society for Reproductive Medicine (ASRM) and its daughter society, the Society for Assisted Reproduction (SART), for the first time published a committee opinion clearly acknowledging that “the value of PGT-A as a routine screening test for patients undergoing in vitro fertilization (IVF) has not been demonstrated.” This statement is timely and welcome but requires some additions and raises some new questions, among those why, if PGT-A in a general population does not improve IVF cycle outcomes, the routine clinical utilization of PGT-A should continue.

Original languageEnglish
JournalJournal of Assisted Reproduction and Genetics
DOIs
StateAccepted/In press - 1 Jan 2024
Externally publishedYes

Keywords

  • Aneuploidy
  • Embryos
  • In vitro fertilization (IVF)
  • Preimplantation genetic testing for aneuploidy (PGT-a)
  • Reproductive medicine
  • Reproductive science

ASJC Scopus subject areas

  • Reproductive Medicine
  • Genetics
  • Obstetrics and Gynecology
  • Developmental Biology
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'An additive opinion to the committee opinion of ASRM and SART on the use of preimplantation genetic testing for aneuploidy (PGT-A)'. Together they form a unique fingerprint.

Cite this